A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Recruiting

Phase 2

VRC07-523LS, PGT121.414.LS, PGDM1400LSA Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT06812494

Conditions

HIV

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

VRC07-523LS 400mg

PGT121.414.LS 400mg

PGDM1400LS 400mg

VRC07-523LS 3200mg

PGT121.414.LS 1600mg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-14. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2026-04-07.